Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial

• DOI: 10.1016/j.euo.2024.07.011
• Publication Date: 2024-08-13T21:44:08Z
• Authors: Stephane Oudard; Yohann Tran; Carole Helissey; Charles Vauchier; Raffaele Ratta; Mostefa Bennamoun; Eric Voog; Ali Hasbini; Antoine Thiery-Vu...; Kais Aldabbagh; Carolina Saldana; Emmanuel Sevin; Eric Amela; Gunhild Von Amsberg; Nadine Houede; Dominique Besson; Susan Feyerabend; Martin Boegemann; David Pfister; Martin Schostak; Olivier Huillard; Frederic Di Fiore; Amandine Quivy; Dewi Vernerey; Antoine Falcoz; Karima Youcef-Ali; Salma Kotti; Eve M. Lepicard; Philippe Barthelemy
• Keywords: Cabazitaxel

The CABASTY study showed that more frequent administration of a lower dose cabazitaxel (CBZ) reduced toxicity in older men with metastatic castration-resistant prostate cancer (mCRPC), without compromising efficacy. Here, we investigated the impact biweekly CBZ schedule on patient-reported pain and health-related quality life (HRQoL).